Eton’s FDA rejection leads July cornea news

Cornea-related news in the month of July included FDA and clinical trial updates, but the most-read cornea story on Healio.com/OSN was the FDA’s rejection of Eton Pharmaceuticals’ allergic conjunctivitis treatment candidate EM-100.

Here are the top five cornea stories of the month:

FDA rejects Eton's allergic conjunctivitis drop

Eton’s partner, Bausch Health Companies, which acquired the U.S. rights to EM-100 in February, received a complete response letter from the FDA regarding the filing. Read more.

Cequa more effective than vehicle in treating dry eye

A significantly higher percentage of patients with dry eye disease treated with OTX-101 experienced significant improvements in tear production and ocular surface integrity than patients treated with vehicle. Read more.

Oyster Point begins dry eye nasal spray phase 3 trial

The multicenter, randomized, double-masked, placebo-controlled ONSET-2 clinical trial will evaluate the safety and efficacy of OC-01 in two doses, 0.6 mg/mL and 1.2 mg/mL, vs. placebo in 750 subjects at 20 U.S. centers. Read more.

Choose the right sunglasses to protect from photokeratitis

To protect the eye from sun damage, sunglasses that block 99% to 100% of both UVA and UVB radiation should be chosen, the American Academy of Ophthalmology said. Oversized glasses also offer more coverage and protection. Read more.

EyeGate files to initiate Ocular Bandage Gel pilot study

EyeGate Pharmaceuticals has filed a protocol with the FDA to initiate a pilot study of its Ocular Bandage Gel eye drop for the treatment of punctate epitheliopathies. Read more.